Senseonics (NYSE:SENS) said this week that won coverage from health plan provider Aetna for its Eversense continuous glucose monitoring system.
Aetna provides coverage for roughly 22 million people in the U.S., according to Senseonics, making it the third largest commercial health plan provider in the country.
“We are pleased that one of the largest national payers in the U.S. is now covering Eversense, and that Aetna recognizes the value of CGM and the value Eversense can bring to the market in terms of patient adherence,” Tim Goodnow, president & CEO of Senseonics, said in prepared remarks. “We believe this coverage decision represents a major milestone and has the potential to facilitate broad patient and physician access to Eversense in the U.S.”
The company’s 90-day, implantable Eversense system, which won FDA approval in June, includes a small sensor that is implanted just below the skin in an outpatient procedure. It continuously measures glucose levels, sending that data to a mobile app every five minutes and alerting users if their glucose levels drop out of range.
Senseonics launched the Eversense system in August and touted that it won coverage for the CGM with Horizon Blue Cross Blue Shield of New Jersey and Horizon Healthcare of New Jersey.
SENS shares were trading at $3.64 apiece in pre-market activity today, up +5.2%.
